Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello, ladies and gentlemen, and welcome to the Autolus ...

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...

This regulatory milestone is the second time BTD has been granted ... including up to 20 times higher risk of developing B-cell lymphomas when compared to the general population. Patients with high ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...

Corporate Highlights Currently 57 patients have been dosed across all cohorts with strong manufacturing success in the FIRCE-1, Phase 2 clinical study of firi-cel in patients with large B-cell ...

This regulatory milestone is the second time BTD has been granted ... including up to 20 times higher risk of developing ...

The increase was due primarily to an increase in manufacturing, clinical, and regulatory costs related to TIDAL-01 clinical ... selection and expansion of the most potent tumor-reactive T cells, known ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

T helper (TH) cells are essential immune cells that help other immune cells function effectively. When activated in response ...

T helper (TH) cells are essential immune cells that help other immune cells function effectively. When activated in response to environmental stimuli, these cells can differentiate into either TH1 ...